Longeveron (LGVN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
August 11, 2023 7:30 AM EDTELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-BÂ in HLHS
Top Line Results for CLEAR MIND Alzheimers disease Phase 2a Trial Anticipated by October 2023
Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions
Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time
MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative... More



